Last reviewed · How we verify
Adalimumab (Humira)
Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine.
Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine. Used for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.
At a glance
| Generic name | Adalimumab (Humira) |
|---|---|
| Also known as | Humira, Trudexa, Anti TNF monoclonal antibodies, HUMIRA®, adalimumab |
| Sponsor | Tufts Medical Center |
| Drug class | TNF-α inhibitor (monoclonal antibody) |
| Target | TNF-α (Tumor Necrosis Factor-alpha) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
By blocking TNF-α, adalimumab reduces the inflammatory cascade that drives autoimmune and inflammatory diseases. This prevents TNF-α from activating immune cells and triggering the production of additional inflammatory mediators, thereby suppressing systemic inflammation and disease progression in conditions like rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
Approved indications
- Rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Crohn's disease
- Ulcerative colitis
- Psoriasis
- Hidradenitis suppurativa
- Juvenile idiopathic arthritis
Common side effects
- Injection site reactions
- Upper respiratory tract infections
- Headache
- Tuberculosis reactivation
- Serious infections
- Malignancy risk
Key clinical trials
- Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt
- Subconjunctival Humira for Boston Keratoprosthesis (PHASE1)
- Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission (NA)
- Intravitreal Adalimumab in Inherited and Degenerative Retinal Diseases (PHASE1, PHASE2)
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (PHASE3)
- Treatment Tapering in JIA With Inactive Disease (PHASE3)
- Preventing Structural Damage in Early Psoriatic Arthritis (PHASE4)
- A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adalimumab (Humira) CI brief — competitive landscape report
- Adalimumab (Humira) updates RSS · CI watch RSS
- Tufts Medical Center portfolio CI